Literature DB >> 1538039

The cost of institutional care in Alzheimer's disease: nursing home and hospital use in a prospective cohort.

H G Welch1, J S Walsh, E B Larson.   

Abstract

OBJECTIVE: To assess the nursing home and hospital use of patients with Alzheimer's Type Dementia.
DESIGN: A prospective cohort study of 126 patients entered into an Alzheimer's disease registry after diagnosis at a university hospital clinic between 1980 and 1982. Only four patients were in nursing homes at enrollment.
MEASUREMENTS AND MAIN RESULTS: Data regarding nursing home use came from the registry and the individual nursing homes themselves. Hospital-use data were obtained using Medicare claims files. Follow-up was obtained on 123 patients (98%). Eighty-five (69%) had died by July 1, 1989. Three-quarters of the cohort (92) eventually resided in nursing homes. The median nursing home length of stay was 2.75 years (mean 2.95, 95% CI = 2.5, 3.4), over 10 times the national median length of stay for all diagnoses. Based on prevailing rates in the region, nursing home charges for the cohort were estimated to be between $4.3 and $6.4 million ($35,000-$52,000 per patient). During the 5-year period 1983-1988, 69 patients filed Part A (hospital) claims to Medicare for 76 admissions and 616 inpatient days. Part A Medicare reimbursement for the cohort totaled $460,000 over 5 years ($3,700 per patient), an expenditure comparable to what a random Medicare cohort might incur.
CONCLUSIONS: The combination of a high rate of nursing home entry and lengthy stays makes long-term care the largest determinant of the cost of care in Alzheimer's disease. While Alzheimer's Type Dementia undoubtedly has profound indirect costs, this study demonstrates that the direct institutional costs alone are considerable.

Entities:  

Mesh:

Year:  1992        PMID: 1538039     DOI: 10.1111/j.1532-5415.1992.tb02072.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  30 in total

Review 1.  The burden of dementia. A medical and research perspective.

Authors:  P Antuono; J Beyer
Journal:  Theor Med Bioeth       Date:  1999-01

2.  Effect of a combined walking and conversation intervention on functional mobility of nursing home residents with Alzheimer disease.

Authors:  R M Tappen; K E Roach; E B Applegate; P Stowell
Journal:  Alzheimer Dis Assoc Disord       Date:  2000 Oct-Dec       Impact factor: 2.703

Review 3.  Dementia in the elderly: the "silent epidemic" no more.

Authors:  E B Larson
Journal:  Trans Am Clin Climatol Assoc       Date:  2001

Review 4.  Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias.

Authors:  R C Dodel; K Berger; W H Oertel
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

5.  The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis.

Authors:  R C Dodel; M Singer; R Köhne-Volland; T Szucs; B Rathay; E Scholz; W H Oertel
Journal:  Pharmacoeconomics       Date:  1998-09       Impact factor: 4.981

6.  Tacrine for Alzheimer's disease. Costs and benefits.

Authors:  D Knopman
Journal:  Pharmacoeconomics       Date:  1995-04       Impact factor: 4.981

Review 7.  The cost of Alzheimer's disease. Will drug treatment ease the burden?

Authors:  W Max
Journal:  Pharmacoeconomics       Date:  1996-01       Impact factor: 4.981

8.  Dementia: a costly problem.

Authors:  C K Hermann
Journal:  Pharmacoeconomics       Date:  1992-12       Impact factor: 4.981

9.  Surgical outcomes for patients diagnosed with dementia: A coarsened exact matching study.

Authors:  Kimon Bekelis; Symeon Missios; Joel Shu; Todd A MacKenzie; Bruce Mayerson
Journal:  J Clin Neurosci       Date:  2018-05-05       Impact factor: 1.961

Review 10.  A systematic review to assess the policy-making relevance of dementia cost-of-illness studies in the US and Canada.

Authors:  Mark Oremus; S Carolina Aguilar
Journal:  Pharmacoeconomics       Date:  2011-02       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.